Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Ophthalmic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for VEGFA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VEGFA Isoforms (165, 121, etc.) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified, HEK293 Expressed. |
View VEGFA Products |
| Gene Delivery | VEGFA Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View VEGFA Products |
| Benchmark Ab | Anti-VEGFA (Sequence of Bevacizumab/Ranibizumab) Recombinant positive control. |
View VEGFA Products |
| Validator | VEGFA siRNA Set For knockdown verification. |
View VEGFA Products |
| VEGFR2 (KDR) | Primary receptor, critical for binding competition assays and downstream signaling. | View VEGFR2 Products |
| ANGPT2 | Synergistic pathway for vascular stabilization (Bispecific target). | View ANGPT2 Products |
| PlGF | Placental Growth Factor, for selectivity screening vs. VEGF family members. | View PlGF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (VEGF121 vs VEGF165) | Sequence-verified isoform proteins (>95% purity) with distinct heparin-binding properties |
| Correct Disulfide Formation & Dimerization | HEK293 Expressed (Native Glycosylation & Dimerization), Theoretical MW strict compliance. |
| Cross-species Cyno/Mouse/Human Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity, sequence verified by MS, for cross-reactivity SPR. |
| High-Concentration Formulation Stability | Low endotoxin (<1EU/ug), aggregation-controlled preps for >50mg/mL screening |
| Family Selectivity (VEGFB/PlGF) | Homolog panel proteins strictly verified by mass spec for off-target screening |
| Lack of Controls | Clinical Benchmark Antibodies (Bevacizumab biosimilar sequence) included for assay baseline setting. |
| False Positives in Neutralization & Non-specific Effects | Endotoxin Controlled (<1EU/ug) ensuring no non-specific cell activation; Validated siRNA included for specificity checks. |
Live VEGFA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VEGFA therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies, long-acting fusion proteins, and sustained-release formulations. While the oncology market is saturated with biosimilars (e.g., Bevacizumab), the ophthalmology sector (Wet AMD, DME) is driving the next wave of R&D, targeting dual-angiogenic pathways and extended durability to reduce intravitreal injection frequency, exploring novel bispecific formats (VEGFA/ANGPT2) and gene therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody / scFv | Roche, Novartis, Amgen, Samsung Bioepis | Colorectal Cancer (mCRC), NSCLC, Wet AMD | Ultra-high affinity kinetics, isoform binding (VEGF165 vs 121), and cyno cross-reactivity (Need pristine HEK293 VEGFA dimers and isoform panel) |
| Fc-Fusion Protein / Trap | Regeneron, Bayer | Wet AMD, DME | Receptor competition and dual-domain binding (Need high-purity VEGFA and VEGFR1/2 for SPR) |
| Bispecific Antibody | Roche (Faricimab) | Wet AMD, DME, Macular Edema | Heterodimer validation and dual binding (Need distinct VEGFA & ANGPT2 antigens) |
| Gene Therapy (AAV) | Regenxbio, AbbVie | Exudative AMD | Expression quantification (Need benchmark Abs for ELISA) |
| siRNA/Aptamer | Formerly Novartis/Opko | Ophthalmology | Potency vs. specific isoforms |